www.inovio.com
Inovio Pharmaceuticals, Inc. is focused on the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent or treat cancers and chronic infectious diseases. This next generation of immunotherapies could potentially protect millions of people from debilitation or death from diseases without adequate treatments.
DNA vaccines have great potential, but two broad challenges must be overcome to achieve development success. First, scientists must further refine immune system targets in order to design DNA vaccines able to induce clinically relevant immune responses. Second, they must improve DNA delivery capabilities to overcome safety and efficacy limitations common to most existing delivery technologies. Inovio's intellectual property, comprised of the knowledge and expertise of its people, its vaccine design and development processes as well as DNA delivery devices, and its patents, positions the company to potentially overcome these challenges and achieve new clinical breakthroughs.
What do others think of Inovio Pharmaceuticals
Presentations & Company Media
21/05/2012
Corporate Profile (Presentation)21/05/2012
PowerPoint Presentation (Presentation)
Related Research & Media
No documents available.
Company Statement:
Inovio is developing its revolutionary vaccines to extend the profound medical benefits of the 20th century's immune-system-stimulating vaccines by preventing and treating today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
Management
J. Joseph Kim, Ph.D.
President, Chief Executive Officer, Director
Mark L. Bagarazzi
Chief Medical Officer
Peter Kies
Chief Financial Officer
Niranjan Y. Sardesai, Ph.D.
Chief Operating Officer
Major Shareholders
No info available.
Contact Information
Inovio Pharmaceuticals, Inc.
Pennsylvania Office
1787 Sentry Parkway West
Building 18, Suite 400
Blue Bell, PA 19422
Telephone
267.440.4200
Toll Free: 877-446-6846
Fax
267.440.4242
Investor Relations:
Toll Free: 877-446-6846
investor.relations@inovio.com
Licensing & Product Information:
new.products@inovio.com
Corporate Information
No info available.
